Our data suggest that PD-1high CAR-T cells are able to produce more IFNγ than PD-1low CAR-T cells, resulting in robust upregulation of ICAM-1 on target cancer cells, which then supports more stable T cell-tumor cell conjugation formations to improve T cell-mediated killing. The gene discussed is ICAM1; the disease is neoplasm.